Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 6.6% – Here’s Why

Posted by Francis Steltz on Oct 15th, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report)’s share price rose 6.6% on Thursday. The stock traded as high as $53.56 and last traded at $54.0420. 7,996 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 206,755 shares. The stock had previously closed at $50.71.

Analyst Ratings Changes

Several research firms have issued reports on DRUG. Wolfe Research initiated coverage on shares of Bright Minds Biosciences in a research report on Thursday. They set an “outperform” rating and a $150.00 price target for the company. Oppenheimer cut Bright Minds Biosciences to a “market perform” rating in a research note on Thursday, August 20th. Lifesci Capital upgraded Bright Minds Biosciences to a “strong-buy” rating in a report on Monday, September 28th. BTIG Research restated a “buy” rating and set a $147.00 price target on shares of Bright Minds Biosciences in a research report on Monday, August 17th. Finally, Wall Street Zen cut Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $144.71.

Get Our Latest Stock Report on Bright Minds Biosciences

Bright Minds Biosciences Trading Up 7.9%

The firm has a market capitalization of $532.53 million, a P/E ratio of -26.34 and a beta of -5.22. The company’s fifty day simple moving average is $65.28 and its 200 day simple moving average is $72.46.

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($1.22) by $1.05. On average, analysts predict that Bright Minds Biosciences Inc. will post -2.93 earnings per share for the current fiscal year.

Institutional Trading of Bright Minds Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of DRUG. Orbimed Advisors LLC bought a new stake in Bright Minds Biosciences during the 1st quarter valued at approximately $2,919,000. Janus Henderson Group PLC lifted its position in Bright Minds Biosciences by 11.1% during the first quarter. Janus Henderson Group PLC now owns 1,284,324 shares of the company’s stock valued at $93,518,000 after buying an additional 128,329 shares during the period. Vivo Capital LLC lifted its position in Bright Minds Biosciences by 11.1% during the first quarter. Vivo Capital LLC now owns 557,172 shares of the company’s stock valued at $40,657,000 after buying an additional 55,555 shares during the period. ADAR1 Capital Management LLC boosted its holdings in shares of Bright Minds Biosciences by 868.6% during the 1st quarter. ADAR1 Capital Management LLC now owns 33,900 shares of the company’s stock valued at $2,474,000 after buying an additional 30,400 shares in the last quarter. Finally, Walleye Capital LLC boosted its holdings in shares of Bright Minds Biosciences by 108.0% during the 1st quarter. Walleye Capital LLC now owns 53,706 shares of the company’s stock valued at $3,919,000 after buying an additional 27,880 shares in the last quarter. 40.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bright Minds Biosciences

(Get Free Report)

Bright Minds Biosciences Inc is a biotechnology company focused on developing next-generation therapeutics for neuropsychiatric and neurological disorders. The company’s research is centered on selective serotonin receptor agonists designed to address conditions involving disrupted brain signaling while potentially avoiding some of the adverse effects associated with older serotonergic medicines.

Bright Minds’ lead product candidate is BMB-101, a selective 5-HT2C receptor agonist being developed for disorders including epilepsy and other conditions involving neuronal hyperexcitability.